Deals, Devices

Danaher hands a distressed GE $21B+ for biopharma business that made $3B last year

GE's recently appointed chief Lawrence Culp is selling the biopharma business of the embattled industrial conglomerate for more than $21 billion to his previous employer, Danaher, a developer of technology for the life sciences industry.

General Electric (GE) — once a beacon of American industry that traces its origins to the assets of celebrated inventor Thomas Edison — has been nursing its wounds of late, as it struggles with mounting debt and insurance liabilities. In desperate need of a cash infusion, the maker of power plants and aircraft engines has been looking to sell off its non-core businesses, and until recently had pledged to pivot its entire health-care business in an initial public offering later in 2019.


In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 47,200+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,200+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->